대한뉴팜

The company announced that its accumulated operating profit for the first half of 2021 reached 13.9 billion won, marking a 13% increase year-on-year. Revenue rose 13% to 83.8 billion won, while net profit grew 19% to 8.9 billion won.

Strong performance continued in the second quarter, with revenue of 44.2 billion won, up 14% from the same period last year. Operating profit increased 8% to 7.2 billion won, and quarterly net profit climbed 22% to 4.7 billion won.

The company attributed its strong results to a focused sales strategy centered on key product lines. Robust sales were reported for Liporase Injection (a wellness injection), Thymosin Injection and Vita d Injection (immune boosters), as well as new and exclusive products including the dyslipidemia combination drug “Newtozet,” the fat absorption inhibitor “Zero be,” and the carbohydrate absorption inhibitor “Migbos Film-Coated Tablet,” which is exclusively marketed in Korea.

In the second half of the year, the company plans to launch its new health supplement brand “DiNU (Define Nutrition)”, built on its pharmaceutical expertise and carrying the slogan “The most ideal health supplement focused on functionality.” New products will roll out sequentially from late August.

Sales of injection products and newly launched items continue to grow steadily, and the company plans to promote “DiNU” aggressively to ensure a successful market entry and further drive revenue growth. Additionally, the relocation of the Central Research Center and Bio Research Center to the Pangyo Industry-Academia Cooperation Center has strengthened the company’s R&D pipeline, underscoring its evolution into a research-driven pharmaceutical enterprise.